Publication
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugRegorafenib Anhydrouscivic_curation1.00
- geneKRAScivic_curation1.00
- variantKRAS G12Acivic_curation1.00
- variantKRAS G12Ccivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantKRAS G12Rcivic_curation1.00
- variantKRAS G12Scivic_curation1.00
- variantKRAS G12Vcivic_curation1.00
- variantKRAS G13Dcivic_curation1.00
- variantKRAS Wildtypecivic_curation1.00
Curated evidence
Evidence citing this paper (8)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26161928
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12A1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID3710In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, repor… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G12C1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID3973In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G12D1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 1 | accepted | EID3946In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 … (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G12R1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 1 | accepted | EID3991In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G12S1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID4012In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G12V1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 2 | accepted | EID3924In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS G13D1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 1 | accepted | EID3889In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |
| KRAS Wildtype1 | ||||||||
| Regorafenib Anhydrous | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8840In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS wildtype did not demonstrate resistance to regorafenib treatment (IC50: 114.28 nM) compared to SW48 cells expressing v… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC | civic |